Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fosrenol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Fosrenol (Lanthanum carbonate) |
| 2 | ACTIVE_COMPARATOR | Sevelamer hydrochloride |
| Name | Type | Description |
|---|---|---|
| Fosrenol (Lanthanum Carbonate) | DRUG | The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets. |
| Sevelamer hydrochloride | DRUG | The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals. |
Inclusion Criteria: * Adults with end stage renal disease who are receiving dialysis Exclusion Criteria: * Subjects with significant gastrointestinal disorders * Subjects who are pregnant or nursing * Subjects currently taking lanthanum carbonate, sevelamer hydrochloride, cinacalcet hydrochloride...
Fosrenol is a small molecule drug being developed for chronic kidney disease, stage 5. It is currently in Phase 3 clinical development and is being studied in patients with this condition.
Fosrenol is being developed by Takeda Pharmaceutical Company Limited, which is publicly traded under the ticker TAK.
Fosrenol is in Phase 3 clinical development. It is an investigational drug and has not been approved for use.
Fosrenol has one completed Phase 3 clinical trial, identified as NCT00441545. This trial was a head-to-head study against sevelamer hydrochloride and enrolled 182 participants with chronic kidney disease, stage 5.
No, Fosrenol is not the same as sevelamer hydrochloride. In clinical trial NCT00441545, Fosrenol was studied head-to-head against sevelamer hydrochloride as an active control.